尽管Gyre Therapeutics在2025年第四季度的收益预期没有实现,但超过了预期的收入,分析师认为收益预期"持久". Gyre Therapeutics missed earnings estimates in Q4 2025 but exceeded revenue forecasts, with analysts holding a "Hold" rating.

Gyre治疗学公司报告说,2025年Q4收入为每股0.04美元,少了8美元的估计数,不过收入为3 720万美元,略高于预期。 Gyre Therapeutics reported Q4 2025 earnings of $0.04 per share, missing the $0.08 estimate, though revenue of $37.20 million slightly exceeded expectations. 该公司的重点是针对新陈代谢、炎症和神经退化疾病的针对脂质的疗法,在NASH、阿尔茨海默氏病和自发免疫条件方面有临床前期方案。 The company, focused on lipid-targeted therapies for metabolic, inflammatory, and neurodegenerative diseases, has preclinical programs in NASH, Alzheimer’s, and autoimmune conditions. 其库存以7.55美元关闭,减少25美元,市场上限为7.2729亿美元,P/E比率为755.76美元。 Its stock closed at $7.55, down $0.25, with a market cap of $727.29 million and a P/E ratio of 755.76. 分析师维持协商一致的“等待”评级,目标价格为17.00美元。 Analysts maintain a consensus "Hold" rating with a $17.00 target price. 会议电话定于2026年3月19日举行。 A conference call is set for March 19, 2026.